Literature DB >> 14984599

Helper T cells, dendritic cells and CTL Immunity.

Georg Behrens1, Ming Li, Christopher M Smith, Gabrielle T Belz, Justine Mintern, Francis R Carbone, William R Heath.   

Abstract

In this review, we examine the emerging view that all CTL responses depend on CD4 T-cell help for the generation of efficient memory. We further review the evidence that CD4 and CD8 T cells must recognize antigen on the same dendritic cell, and examine why this corecognition is required. Earlier studies have suggested that CD4 T cells must activate the dendritic cell via CD40 to license it for the capacity to prime CTL immunity. More recently, however, CD40 signalling of the CTL has been reported. Here, we argue that the main reason for corecognition of antigen on the dendritic cell may be related to the time taken to activate and release CD4 and CD8 T cells from their priming dendritic cell. CD4 T cells may only be capable of activating one dendritic cell during the period that CD8 T cells are primed. In this case, corecognition of this same dendritic cell would be essential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984599     DOI: 10.1111/j.1440-1711.2004.01211.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  34 in total

1.  Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

Authors:  William K Decker; Dongxia Xing; Sufang Li; Simon N Robinson; Hong Yang; David Steiner; Krishna V Komanduri; Elizabeth J Shpall
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

2.  CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input.

Authors:  Yosuke Kumamoto; Lisa M Mattei; Stephanie Sellers; Geoffrey W Payne; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

Review 3.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Authors:  Paul Andrew Antony; Nicholas P Restifo
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

4.  CD4⁺ and CD8⁺ T cell-dependent antiviral immunity requires STIM1 and STIM2.

Authors:  Patrick J Shaw; Carl Weidinger; Martin Vaeth; Kevin Luethy; Susan M Kaech; Stefan Feske
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

5.  Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells.

Authors:  Angel Padilla; Dan Xu; Diana Martin; Rick Tarleton
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

Review 6.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

7.  Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Yanjun Liu; Z Sheng Guo; David L Bartlett; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

8.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

9.  Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; Lisa Rollins; Wenhong Ren; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.